The biotech sector spent the better part of three years locked out of the public markets. That era appears to be decisively over. Eighteen biotech companies completed initial public offerings in the first half of 2026, exactly double the eight that went public during the same period in 2025, according to data from BioSpace. Two of those listings, Kailera Therapeutics at $625 million and Parabilis Medicines at $670 million, shattered the previous record for the largest biotech IPO ever, a title Moderna had held since 2018.
The numbers are not just higher in volume. They are higher in conviction. The median biotech IPO in 2026 raised approximately $287.5 million, more than double the equivalent figure from early 2025 and the highest quarterly median since the pandemic-era peak of 2021. Eleven of the thirteen venture-backed biotechs that priced offerings in the first half secured at least $250 million. Investors are writing larger checks for fewer companies, and the companies receiving that capital are performing after they get to Wall Street. Most of the 2026 class is currently trading at or above its debut price.
Why the Window Opened
Two forces converged to create this environment, and they are reinforcing each other. The first is a surge in mergers and acquisitions. In Q1 2026 alone, the biopharma sector recorded 19 exits valued at $13.3 billion, the highest exit value since the fourth quarter of 2021. Deals like GSK’s $10.6 billion acquisition of Nuvalent and AbbVie’s $10.9 billion purchase of Apogee Therapeutics have demonstrated that large pharma will pay significant premiums for clinical-stage assets in high-priority therapeutic areas. That M&A activity is directly fueling IPO appetite because the companies going public increasingly resemble the exact profiles that large pharma is hunting.
The second force is a return to regulatory predictability at the FDA. The agency has moved toward greater use of advisory committees and is re-evaluating applications that previously received complete response letters, creating a more navigable path for companies with mid-to-late-stage clinical programs. The combination of active acquirers and a more transparent regulatory environment has restored investor confidence in the sector’s ability to generate returns.
What It Means for Existing Small Cap Biotechs
The implications extend well beyond the companies actually going public. A healthy IPO market lifts the entire clinical-stage biotech ecosystem. When newly public companies trade well, it signals to institutional investors that the sector is functioning again, which draws capital back into the broader small cap biotech universe, including the hundreds of companies already listed and advancing their own programs.
The therapeutic areas attracting the most capital align closely with where patent cliffs are creating the most urgency for large pharma acquirers. Oncology remains a dominant focus, with companies like Cardiff Oncology, MAIA Biotechnology, and Greenwich LifeSciences all advancing clinical programs in areas where large pharma has demonstrated a clear willingness to pay for innovation. Cardiovascular disease emerged as a significant theme in H1, with Kardigan’s $400 million offering anchored around late-stage cardiac assets. Immunology, neuroscience, and rare disease continue to draw investor interest as well, with companies like Eledon Pharmaceuticals developing differentiated programs in therapeutic areas where unmet need and commercial opportunity intersect.
The second half is expected to accelerate further. Nasdaq has estimated that a dozen additional biotech IPOs could price in Q3 alone, and companies like Scribe Therapeutics, co-founded by CRISPR pioneer Jennifer Doudna, are already in the filing process. The biotech funding window has not been this open since 2021. The difference this time is that the market is rewarding discipline, clinical data, and clear regulatory paths rather than early-stage platforms and promises. That distinction is what makes this cycle more durable than the last one.
